MacroGenics, Inc.

MGNX

US5560991094

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-28 pm EDT			5-day change	1st Jan Change
4.25 ^USD	+3.16%		-2.75%	-55.82%

Jun. 24	MacroGenics, Inc.(NasdaqGS:MGNX) dropped from S&P Biotechnology Select Industry Index	CI
Jun. 13	Transcript : MacroGenics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 10:00 AM

MacroGenics, Inc.(NasdaqGS:MGNX) dropped from S&P Biotechnology Select Industry Index

June 23, 2024

Latest news about MacroGenics, Inc.

MacroGenics, Inc.(NasdaqGS:MGNX) dropped from S&P Biotechnology Select Industry Index	Jun. 23	CI
Transcript : MacroGenics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 10:00 AM	Jun. 13
Sector Update: Health Care Stocks Higher Late Afternoon	May. 10	MT
Sector Update: Health Care	May. 10	MT
Top Midday Decliners	May. 10	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	May. 10	MT
Wall Street Set to Extend Gains on Thursday's Higher-Than-Expect Jobless Claims Report, Lifting US Equity Futures Pre-Bell	May. 10	MT
Top Premarket Decliners	May. 10	MT
BMO Downgrades MacroGenics to Market Perform From Outperform, Price Target at $8	May. 10	MT
Stifel Downgrades MacroGenics to Hold	May. 10	MT
TD Cowen Downgrades MacroGenics to Hold From Buy	May. 10	MT
MacroGenics Says Five Patients Died in Cancer Study	May. 10	MT
MacroGenics Q1 Loss Widens, Revenue Falls	May. 10	MT
Transcript : MacroGenics, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Earnings Flash (MGNX) MACROGENICS Posts Q1 Revenue $9.1M, vs. Street Est of $14.9M	May. 09	MT
MacroGenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
B. Riley Securities Initiates MacroGenics With Buy Rating, $25 Price Target	Apr. 26	MT
North American Morning Briefing : Traders Await -2-	Apr. 10	DJ
TD Cowen Upgrades MacroGenics to Buy From Hold	Apr. 09	MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Apr. 04	MT
MacroGenics Shares Surge Following Phase 2 Update on Prostate Cancer Drug	Apr. 04	MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Thursday	Apr. 04	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Renewed Rate Cut Hopes	Apr. 04	MT
Sector Update: Health Care	Apr. 04	MT
MacroGenics Says Cancer Drug Study Update Set for May After Conference Miss	Apr. 03	MT

MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for MacroGenics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.25 USD

Average target price

10.8 USD

Spread / Average Target

+154.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MACROGENICS, INC.	-55.82%	266M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs

MacroGenics, Inc.

Equities

MGNX

US5560991094

Biotechnology & Medical Research

MacroGenics, Inc.(NasdaqGS:MGNX) dropped from S&P Biotechnology Select Industry Index

Latest news about MacroGenics, Inc.

Chart MacroGenics, Inc.

Company Profile

Income Statement Evolution

Ratings for MacroGenics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs